Semax is a synthetic heptapeptide derived from the adrenocorticotropic hormone (ACTH 4-7) with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Originally developed by the Russian Academy of Sciences in the 1980s, it has been the subject of extensive preclinical and clinical research, particularly in Russia and Eastern Europe.
Research suggests Semax exerts its effects through several pathways. Studies indicate it significantly upregulates Brain-Derived Neurotrophic Factor (BDNF) and its receptor TrkB in the hippocampus and frontal cortex. BDNF plays a critical role in neuronal survival, growth, and synaptic plasticity.
Additionally, research has demonstrated Semax's influence on dopaminergic and serotonergic systems, potentially modulating mood and cognitive function. Some studies suggest it increases cerebral blood flow and has neuroprotective properties against ischemic damage.
Key research finding: A 2001 study published in the Bulletin of Experimental Biology and Medicine demonstrated that Semax administration significantly increased BDNF mRNA levels in rat brain tissue, with effects persisting for up to 24 hours post-administration.
The nasal route has been widely used in Semax research due to the rich vascularisation of the nasal mucosa and the potential for direct transport via the olfactory pathway to the central nervous system, bypassing the blood-brain barrier.
In research settings, intranasal administration is typically achieved using a standard nasal atomiser. The peptide is reconstituted in bacteriostatic water before administration.
Many researchers studying Semax also investigate Selank (a tuftsin-based heptapeptide) as a complementary compound. While Semax research focuses on stimulatory and neuroprotective effects, Selank research centres on anxiolytic and GABAergic modulation. The two peptides are frequently studied together in cognitive research models.
PureAura supplies pharmaceutical-grade Semax for in vitro research. 99%+ purity, COA verified, EU delivery.
View Semax →Semax remains an active area of research interest. Current studies are exploring its potential applications in models of neurodegeneration, stroke recovery, and cognitive decline. Its favourable safety profile in preclinical studies has maintained research interest over several decades.
Disclaimer: This article is for informational and educational purposes only. All PureAura products are sold strictly for in vitro laboratory research use. They are not medicines and are not approved for human administration. This content does not constitute medical advice. Always consult a qualified healthcare professional for medical guidance.